Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06823089 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of Cartilage Defect Repair
A NA study of Osteoarthritis, Hip and Femoroacetabular Impingement, sponsored by Cytex Therapeutics.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06823089: Recruiting NA study of Osteoarthritis, Hip and Femoroacetabular Impingement, sponsored by Cytex Therapeutics.
NCT06823089 is a NA study of Osteoarthritis, Hip and Femoroacetabular Impingement that is actively recruiting participants, run by Cytex Therapeutics. The registered enrollment target is 15 participants, below the 1,273-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06823089, a NA study of Osteoarthritis, Hip and Femoroacetabular Impingement, is actively recruiting participants, sponsored by Cytex Therapeutics.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed conservative care, and is a candidate for surgical intervention to treat.
Primary Outcome
Incidence rate of all adverse events including general adverse events, procedure related events and device related events. Incidence rate of device-related serious adverse events
Conditions Studied
Interventions
- DEVICE ReNew Hip Implant
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2031-10 |
| Phase | NA |
What NCT06823089 shows while recruiting
NCT06823089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,273-participant average among 20 other Osteoarthritis, Hip trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Osteoarthritis, Hip appearing as the primary indexed condition, and to 1 intervention - of which ReNew Hip Implant is the first listed.
NCT06823089 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06823089 about?
NCT06823089 is a clinical study titled "Early Feasibility Study of Cartilage Defect Repair". Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed conservative care, and is a candidate for surgical intervention to treat.
What is the current status of trial NCT06823089?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-11-06. Estimated completion is 2031-10.
What conditions does trial NCT06823089 study?
This clinical trial studies the following conditions: Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Hip Dysplasia, Legg-Calvé-Perthes Disease.
What interventions are being tested in trial NCT06823089?
The interventions under investigation include: ReNew Hip Implant (DEVICE).
Who is sponsoring clinical trial NCT06823089?
This trial is sponsored by Cytex Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06823089 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Hip
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06823089's enrollment target sits among peer trials
15 21st of 20 the lowest of 20 other Osteoarthritis, Hip trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Hip trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Effectiveness of the HIT Reverse HRS
RECRUITING · NA
-
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion
RECRUITING · NA
-
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
RECRUITING · NA
-
Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and/or Hip Pain
RECRUITING · NA
-
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
RECRUITING · NA
-
Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI